Efficacy and safety of valsartan as an antiproteinuric agent in children aged 3 to 18 years with minimal change nephrotic syndrome

ABSTRACT

Background: Nephrotic syndrome is primarily a pediatric disorder which causes heavy proteinuria hypoalbuminemia, edema, and hyperlipidemia. Most children [90%] with nephrotic syndrome have idiopathic nephrotic syndrome caused in 85% of the patients by minimal change glomerular disease. Valsartan is an angiotensin II receptor blocker approved in adults for the treatment of hypertension, heart failure and it may also reduce proteinuria in nephritic syndrome